Abstract:BACKGROUND: Sufficient dose of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid regimen may be an ideal treatment option for renal transplant recipients, and the regimen has been widely used in clinic due to its low nephrotoxicity, few adverse reactions and strong immunosuppressive effects. OBJECTIVE: To investigate the efficacy and safety of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid regimen in renal transplantation patients with the control of mycophenolate mofetil combined with standard-dose tacrolimus and corticosteroid. METHODS: A total of 210 patients receiving a single-organ renal al ograft were randomly divided into standard-dose tacrolimus group (n=104) and low-dose tacrolimus group (n=106). Individual patients were treated for 12 months. The primary efficacy endpoints were the chronic al ograft damage index and glomerular filtration rate at 12 months after transplantation. The secondary efficacy end points mainly included the acute rejection rate, treatment failure rate, and the survival rate of patient and transplant kidney. The safety parameters such as new onset of post-transplantation diabetes mel itus, hypertension and hyperlipidemia were also evaluated. RESULTS AND CONCLUSION: The vast majorities of patients were administrated with sufficient dose of mycophenolate mofetil (1.5 g/d or above) in two groups. The majority of the patients in standard-dose tacrolimus group had the mean trough level below the protocol-defined, which led to the similar mean trough level between standard-dose and low-dose tacrolimus group. These could also confirm that the regimen of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid had been wildly accepted and used by clinicians. The efficacy and safety of two groups were similar. The mean chronic al ograft damage index of the renal pathological changes at 12 months after transplantation in standard-dose and low-dose tacrolimus group were 1.82 and 2.13 respectively (P=0.081 3), the mean glomerular filtration rates were 77.08 mL/min and 80.12 mL/min (P=0.794 9), acute rejection rates were 2.6% and 5.2% (P=0.681 2), and the survival rates of patients and transplant kidney were 100% and 99.1% (P=1.000 0). The rates of new onset of post-transplantation diabetes mel itus in the standard-dose and low-dose tacrolimus group were 2.9% and 1.9%, and the rates of hyperlipidemia were 2.9% and 3.8%, respectively. For the regimen of mycophenolate mofetil combined with tacrolimus and corticosteroid, the utilization of sufficient dose of mycophenolate mofetil could reduce the dose of tacrolimus, thereby significantly reducing the nephrotoxicity, hyperlipidemia and new onset of post-transplantation diabetes mel itus caused by tacrolimus and achieving a good balance of efficacy and toxicity when maintaining a strong immune inhibition and reducing the acute rejection incidence successful y.

Successful reversal of acute vascular rejection in a renal allograft with combined mycophenolate mofetil and tacrolimus as primary immunotherapy

Efficacy of Ctla4-Ig in Preventing Acute Rejection of Fully Allogeneic Heart Allografts in Sensitized Recipients

Treatment of Early Mixed Cellular and Humoral Renal Allograft Rejection with Tacrolimus and Mycophenolate Mofetil.

Advances in the Treatment of Acute and Chronic Rejection for Vascularized Organ Allografts

Tacrolimus Combined with Mycophenolate Mofetil Can Effectively Reverse C4d-positive Steroid-Resistant Acute Rejection in Chinese Renal Allograft Recipients.

Rescue Therapy by Immunoadsorption in Combination with Tacrolimus and Mycophenolate Mofetil for C4d-Positive Acute Humoral Renal Allograft Rejection

Novel Rescue Therapy for C4d-Positive Acute Humoral Renal Allograft Rejection

Application of Mycophenolate Mofetil Combined with Low-Dose Tacrolimus and Corticosteroid Regimen after Renal Transplantation

Helper T Cell (CD4 + ) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity

Effect of Switch from Cyclosporine to FK506 on Renal Graft Outcome in Patients after Initial Acute Rejection

Effect of Tacrolimus As Rescue Therapy in Patients with Acute Accelerating Allograft Renal Rejection

Clinical outcomes in renal allograft recipients switched to long-term immunosuppressive therapy with mycophenolate mofetil after renal transplantation

Tacrolimus As Rescue Therapy for Adult-Onset Refractory Minimal Change Nephrotic Syndrome with Reversible Acute Renal Failure.

Effect of acute humoral rejection on renal allograft survival

Mycophenolate mofetil for prevention and treatment of rejection of the graft and its safety in renal transplant recipients

The Prospective Randomized Study on Prevention of Cadaveric Renal Allograft Rejection by Tacrolimus (FK506)

Successful renal transplantation in a patient with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis: effect of early plasma exchange and mycophenolate mofetil.

Immunoadsorption and Tacrolimus-Mycophenolate-methylprednisolone Rescue for Accelerated Acute Rejection in Kindeny Transplantation

Prevention of Acute and Chronic Rejection of Rat Heart Allografts by Oral Administration of Tolerogenic Donor Recipient Allochimeric Class I Mhc Proteins

Reversal of accelerated renal allograft rejection with FK 506

Conversion from Cyclosporine to Tacrolimus in Renal Allograft Recipients with Chronic Allograft Nephropathy: A Prospective Single Center Study